Get the Stockscreener App
22.70
1.13%
-0.26
Catalyst Pharmaceuticals Inc stock is traded at $22.70, with a volume of 877.92K.
It is down -1.13% in the last 24 hours and down -6.16% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$22.96
Open:
$22.99
24h Volume:
877.92K
Relative Volume:
0.72
Market Cap:
$2.79B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
19.24
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
-0.09%
1M Performance:
-6.16%
6M Performance:
+7.18%
1Y Performance:
+0.18%
1-Day Range:
$22.68
$23.16
1-Week Range:
$22.13
$23.31
52-Week Range:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.70 | 2.82B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock” - Insider Monkey
First Week of September 18th Options Trading For Catalyst Pharmaceuticals (CPRX) - Nasdaq
SG Americas Securities LLC Raises Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Fundamentals with a Technical Breakout Setup - Chartmill
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - sharewise.com
Short Squeeze: What is the next catalyst for Actinium Pharmaceuticals IncProfit Target & Technical Confirmation Trade Alerts - baoquankhu1.vn
Bank Watch: Is Catalyst Pharmaceuticals Inc. stock influenced by commodity pricesJuly 2025 Review & Weekly Momentum Picks - baoquankhu1.vn
Catalyst Pharmaceuticals, Inc. Presents at JP Morgan Healthcare Conference - TradingView — Track All Markets
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Forbes 2026 Small Cap Recognition - Sahm
Will Catalyst Pharmaceuticals Inc. stock see insider buyingQuarterly Trade Summary & Daily Stock Trend Reports - Улправда
How Catalyst Pharmaceuticals Inc. stock benefits from tech adoption2025 Trading Recap & Fast Momentum Stock Entry Tips - Улправда
Does Forbes’ Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? - Yahoo Finance
How Forbes’ Small-Cap Accolade Will Impact Catalyst Pharmaceuticals (CPRX) Investors - Sahm
Will Catalyst Pharmaceuticals Inc. stock benefit from green energy trendsEntry Point & Consistent Profit Trading Strategies - Улправда
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? - AOL.com
How Catalyst Pharmaceuticals Inc. stock performs in rising dollar environmentTrade Exit Report & Verified Chart Pattern Trade Signals - ulpravda.ru
Funds from operations of Catalyst Pharmaceuticals, Inc. – FWB:CN2 - TradingView — Track All Markets
Is Catalyst Pharmaceuticals Inc. stock a buy before product launchesJuly 2025 Market Mood & Real-Time Market Trend Scan - ulpravda.ru
Will Catalyst Pharmaceuticals Inc. stock maintain dividend yield2025 Geopolitical Influence & Free Community Consensus Stock Picks - Улправда
Santhera Seals APAC Pact For Agamree - Citeline News & Insights
Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now? - Yahoo Finance
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies - The Manila Times
Catalyst Pharmaceuticals Receives Prestigious Ranking on - GlobeNewswire
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Prospects Need A Boost To Lift Shares - 富途牛牛
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Cross Above 200-Day Moving AverageHere's Why - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) - The Manila Times
Aug PreEarnings: Is Catalyst Pharmaceuticals Inc CN2 stock a contrarian opportunityJuly 2025 Retail & Weekly High Return Forecasts - moha.gov.vn
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? - The Motley Fool
Aug Closing: Why Catalyst Pharmaceuticals Inc stock remains resilient2025 Earnings Surprises & AI Powered Market Entry Strategies - moha.gov.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade - ts2.tech
Exchange Traded Concepts LLC Grows Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - MSN
Voya Investment Management LLC Has $8.79 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Texas Permanent School Fund Corp Boosts Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Wedge Capital Management L L P NC Makes New $2.86 Million Investment in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains - 富途牛牛
First Week of February 2026 Options Trading For Catalyst Pharmaceuticals (CPRX) - Nasdaq
Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Stock Pick - Chartmill
Market Fear: Can Catalyst Pharmaceuticals Inc. stock outperform in 2025 bull marketPortfolio Return Summary & AI Powered Market Entry Ideas - Улправда
Market Fear: Will Catalyst Pharmaceuticals Inc CN2 stock sustain bullish trend into 2025Quarterly Profit Review & Consistent Growth Stock Picks - moha.gov.vn
Can Catalyst Pharmaceuticals Inc. stock outperform in 2025 bull marketJuly 2025 Price Swings & Daily Momentum Trading Reports - Улправда
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now - MSN
Why Catalyst Pharmaceuticals Inc. stock remains resilientQuarterly Market Summary & Safe Entry Momentum Stock Tips - DonanımHaber
What hedge fund moves indicate for Catalyst Pharmaceuticals Inc. (CN2) stock2025 Technical Patterns & Growth Focused Entry Reports - DonanımHaber
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):